

## **MENDUS AB (PUBL) HAS RESOLVED TO TRANSFER OWN SHARES ON NASDAQ STOCKHOLM**

**The board of directors of Mendus AB (publ) ("Mendus") has decided, based on the authorization from the Annual General Meeting on 6 May 2025, to transfer own shares on Nasdaq Stockholm.**

In order to give Mendus the possibility to sell own shares to preserve cash with respect to payment in cash to the employees and board members that have chosen to receive their bonus and remuneration, respectively, paid in cash as well as hedge payments of taxes and other costs related to the payment of the bonus and remuneration, the Annual General Meeting on May 6, 2025 resolved to authorize the board of directors, at one or more occasions during the period until the next Annual General Meeting, to transfer own shares on Nasdaq Stockholm.

Based on the authorization from the Annual General Meeting on 6 May 2025, the board of directors has decided to transfer up to 1,200,000 own shares at Nasdaq Stockholm. The shares will be transferred during the period 21 August 2025 – 30 April 2026 at a price per share within the registered price interval at any given time. No sales will take place during 30 days prior to the publication of a financial report. The transfer of shares will be executed discretionary by DNB Bank ASA and will be reported via Nasdaq Stockholm in accordance with applicable rules.

At the time of this press release, there are 52,084,578 shares in Mendus, all which are ordinary shares. At the time of this press release, Mendus holds 1,350,549 shares.

**For more information, please contact:**

Erik Manting

Chief Executive Officer

E-mail: [ir@mendus.com](mailto:ir@mendus.com)

**About Mendus AB (publ)**

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. <https://www.mendus.com/>